Top Markets
#1 Cross Cross +12.78%
#2 Casper Network Casper Network +11.85%
#3 Gama Token Gama Token +9.13%
#4 龙虾 (Lobster) 龙虾 (Lobster) +5.14%
#5 Perle Perle +4.54%
#6 Berachain Berachain +4.52%
#7 Akedo Akedo +4.17%
#8 Humanity Humanity +3.77%
#9 The Innovation Game The Innovation Game +3.74%
#10 Palladium Network Palladium Network +3.67%
Coin of the day
Cross Cross
Settings
Language
ENGLISH
Currency
USD
Theme
Eiger BioPharmaceuticals, Inc. Eiger BioPharmaceuticals, Inc.

Eiger BioPharmaceuticals, Inc.

EIGR
Rank in Stocks #36561
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company... Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and bringing to market targeted therapies for rare and ultra-rare diseases across the United States and internationally. Its primary investigational drug, Lonafarnib, an orally administered small molecule, is currently undergoing Phase III clinical trials for the treatment of hepatitis delta virus (HDV) infection. Other promising candidates in its portfolio include Lambda, which has completed Phase II clinical trials and is designed to target type III interferon receptors; Lonafarnib, also being evaluated for progeria and progeroid laminopathies; and Avexitide, an agent for congenital hyperinsulinism that has also successfully concluded Phase II studies for post-bariatric hypoglycemia. Established in 2008, Eiger BioPharmaceuticals, Inc. maintains its headquarters in Palo Alto, California.
Share Price
$1.73
Last synced: 2025-06-17
Market Cap
$2.55M
Change (1 day)
-0.29%
Change (1 year)
0.00%
Country
US
Trade Eiger BioPharmaceuticals, Inc. (EIGR)

Category

Healthcare
Revenue for Eiger BioPharmaceuticals, Inc. (EIGR)
Revenue in Aug 2026 TTM: 0
According to Eiger BioPharmaceuticals, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Eiger BioPharmaceuticals, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE